Gilead Sciences (GILD) Gross Margin Growth (3y) (2012 - 2026)

Gilead Sciences (GILD) Gross Margin Growth (3y) (2012 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin Growth (3y) (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 338.00
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 531.00
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn -168.00
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 449.00
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 134.00
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn -367.00
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 129.00
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn -1,698.00
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn -714.00
10 Novartis Ag 109.78 Bn 109.09 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2026 129.00
Dec 31, 2025 -160.00
Sep 30, 2025 -39.00
Jun 30, 2025 184.00
Mar 31, 2025 -149.00
Dec 31, 2024 1,538.00
Sep 30, 2024 -438.00
Jun 30, 2024 16.00
Mar 31, 2024 -202.00
Dec 31, 2023 -1,054.00
Sep 30, 2023 -485.00
Jun 30, 2023 -116.00
Mar 31, 2023 -459.00
Dec 31, 2022 973.00
Sep 30, 2022 -134.00
Jun 30, 2022 -544.00
Mar 31, 2022 -349.00
Dec 31, 2021 -917.00
Sep 30, 2021 293.00
Jun 30, 2021 -118.00